相似文献
1
Gene Silencing Therapy in Hereditary (Variant) Transthyretin Cardiac Amyloidosis: A Puzzling Case of Decreasing Pyrophosphate Uptake on Scintigraphy.
Circ Cardiovasc Imaging. 2023 Aug;16(8):e015243. doi: 10.1161/CIRCIMAGING.123.015243. Epub 2023 Jun 19.
2
Tafamidis Treatment Decreases Tc-Pyrophosphate Uptake in Patients With Hereditary Ala97Ser Transthyretin Amyloid Cardiomyopathy.
JACC Cardiovasc Imaging. 2023 Jun;16(6):866-867. doi: 10.1016/j.jcmg.2022.12.016. Epub 2023 Feb 8.
3
Hereditary cardiac amyloidosis associated with Pro24Ser transthyretin mutation: a case report.
J Med Case Rep. 2018 Dec 16;12(1):370. doi: 10.1186/s13256-018-1931-5.
4
Serial Technetium Pyrophosphate Scintigraphy and Multimodality Assessments After Different Doses of Tafamidis for Variant Transthyretin Cardiac Amyloidosis.
Circ Heart Fail. 2023 Jan;16(1):e009595. doi: 10.1161/CIRCHEARTFAILURE.122.009595. Epub 2022 Dec 21.
5
Low-sensitivity 99mTc pyrophosphate scintigraphy for hereditary transthyretin cardiac amyloidosis with Glu112Lys genotype.
Eur Heart J Cardiovasc Imaging. 2024 Feb 22;25(3):e115. doi: 10.1093/ehjci/jead295.
6
(99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses.
Circ Cardiovasc Imaging. 2013 Mar 1;6(2):195-201. doi: 10.1161/CIRCIMAGING.112.000132. Epub 2013 Feb 11.
7
Monitoring of cardiac transthyretin amyloid load by [Tc]DPD scintigraphy: is it the end of the semi-quantitative evaluation?
Amyloid. 2022 Sep;29(3):210. doi: 10.1080/13506129.2022.2055460. Epub 2022 Mar 24.
8
Mutant Thr95Ile Transthyretin-Related Cardiac Amyloidosis With Polyneuropathy.
Circ J. 2019 Oct 25;83(11):2328. doi: 10.1253/circj.CJ-19-0281. Epub 2019 Jun 26.
9
Non-invasive detection and differentiation of cardiac amyloidosis using Tc-pyrophosphate scintigraphy and C-Pittsburgh compound B PET imaging.
Amyloid. 2020 Dec;27(4):266-274. doi: 10.1080/13506129.2020.1798223. Epub 2020 Jul 28.
10
First Norwegian case of hereditary ATTR amyloidosis with a novel transthyretin variant.
Scand Cardiovasc J. 2023 Dec;57(1):2174269. doi: 10.1080/14017431.2023.2174269.
引用本文的文献
1
Impact of Tafamidis on [Tc]Tc-pyrophosphate Scintigraphy in Ala97Ser Hereditary Transthyretin amyloid cardiomyopathy: significant initial reduction with stable Long-Term effects.
Eur J Nucl Med Mol Imaging. 2025 Apr;52(5):1853-1863. doi: 10.1007/s00259-025-07079-4. Epub 2025 Jan 13.
2
Use of Technetium-99m-Pyrophosphate Single-Photon Emission Computed Tomography/Computed Tomography in Monitoring Therapeutic Changes of Eplontersen in Patients With Hereditary Transthyretin Amyloid Cardiomyopathy.
J Am Heart Assoc. 2024 Jan 16;13(2):e030512. doi: 10.1161/JAHA.123.030512. Epub 2024 Jan 12.
本文引用的文献
1
Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial.
Amyloid. 2023 Mar;30(1):1-9. doi: 10.1080/13506129.2022.2091985. Epub 2022 Jul 23.
2
Cardiac microcalcifications in transthyretin (ATTR) amyloidosis.
Int J Cardiol. 2022 Apr 1;352:84-91. doi: 10.1016/j.ijcard.2022.01.036. Epub 2022 Jan 22.
Zotero 插件